Letrozol Heumann (Letrozole)

Letrozole blocks the aromatase enzyme, which converts adrenal and ovarian androgens into estrogen. By suppressing this conversion, circulating estrogen concentrations fall, depriving hormone‑sensitive breast cancer cells of the estrogenic stimulus required for their proliferation.

The specific dose of Letrozol Heumann is determined by the prescribing physician based on the patient’s clinical condition, renal and hepatic function, and treatment goals. Healthcare providers follow established guidelines but individual dosing is personalized.

Letrozol Heumann is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to known teratogenic risk. It is also not recommended for breastfeeding women because the drug can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozole is a third‑generation aromatase inhibitor with a high potency and a long half‑life, offering once‑daily oral dosing. Compared with earlier agents such as anastrozole, letrozole often provides slightly greater estrogen suppression, though clinical choice depends on patient tolerance, comorbidities and physician preference.

Letrozol Heumann should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Letrozol Heumann is taken orally, usually as a tablet swallowed with water. It is generally administered once daily, with or without food, as directed by the treating physician.

Serious risks include severe liver injury, osteoporosis leading to fractures, deep‑vein thrombosis or pulmonary embolism, and rare allergic reactions such as anaphylaxis. Patients should report any signs of jaundice, sudden bone pain, swelling of the limbs, or difficulty breathing to their healthcare provider promptly.

Letrozol Heumann should not be used by pregnant women, nursing mothers, or individuals with known hypersensitivity to letrozole or any excipients. Caution is advised in patients with severe liver impairment, uncontrolled osteoporosis, or those taking strong CYP2C19 inducers or inhibitors without appropriate monitoring.